Big announcement

1. Cinda Biotech: Total product revenue in the third quarter exceeded 1.6 billion yuan, a year-on-year increase of more than 45%

$INNOVENT BIO (01801.HK)$It was announced that in the third quarter of this year, total product revenue was over 1.6 billion yuan, an increase of 45% year-on-year. Significant month-on-month growth was also maintained, and marketing output and efficiency continued to improve. Dabershu (cindilizumab injection) maintained strong sales performance and a solid market leading position during the quarter, while overall sales of other products also increased significantly.

2. Auto Home: Total net revenue for Q3 in 2023 was 1,906 billion yuan, up 3.42% year on year

$AUTOHOME-S (02518.HK)$According to the announcement, the total net revenue for Q3 in 2023 was 1,906 million yuan, compared to 1,843 million yuan for the same period last year; net profit attributable to the company was 578 million yuan, the same period last year was 508 million yuan; net profit attributable to common shareholders was 564 million yuan, compared to 495 million yuan for the same period last year; and adjusted net profit attributable to the company was 604 million yuan, compared to 590 million yuan for the same period last year.

3. Vanke Enterprise: From January to October, it achieved cumulative contract sales of 312.44 billion yuan

$CHINA VANKE (02202.HK)$An announcement was issued. In October 2023, the company achieved a contract sales area of 2.0000 square meters and a contract sales amount of RMB 31.83 billion, a year-on-year decrease of 0.84%. From January to October 2023, the company achieved a total contract sales area of 1,884 million square meters, and contract sales amount of RMB 312.44 billion, a decrease of 9.9% over the previous year.

4. Jiumaojiu: Intended repurchase of company shares not exceeding HK$150 million

$JIUMAOJIU (09922.HK)$An announcement was issued that on November 2, 2023, the board of directors of the company resolved to exercise the powers granted to the board of directors under the general authorization granted to the board of directors in accordance with the resolution passed by the company's shareholders at the company's annual general meeting held on June 2, 2023, to repurchase the company's shares on the open market from time to time for a maximum total amount of HK$150 million.

Earnings Report

$AUTOHOME-S (02518.HK)$: Total net revenue for Q3 in 2023 was 1,906 billion yuan, up 3.42% year on year

$INNOVENT BIO (01801.HK)$Total product revenue in the third quarter exceeded 1.6 billion yuan, a year-on-year increase of more than 45%

Operational data

$CHINA VANKE (02202.HK)$: From January to October, contract sales reached a total of 312.44 billion yuan

$HOPSON DEV HOLD (00754.HK)$Total contract sales for the first 10 months were 26.72 billion yuan

$YUEXIUTRANSPORT (01052.HK)$: Humen Bridge's September toll revenue of 81.55 million yuan increased 15.9% year-on-year

Pharmaceutical Innovation

$GENSCRIPT BIO (01548.HK)$: Legendary Creatures will announce the results of research and development updates

$HANSOH PHARMA (03692.HK)$“Tedizolomide phosphate for injection” obtained a drug registration certificate

$GRANDPHARMA (00512.HK)$: The clinical trial application of ARC01, the global innovative therapeutic tumor vaccine, in China was accepted by the Drug Administration

$GAUSH MEDITECH (02407.HK)$: Rigid corneal contact lenses obtained a medical device registration certificate from the State Drug Administration

$IVD MEDICAL (01931.HK)$Signed a number of agreements with Heeson Mikon Shanghai for strategic cooperation in the coagulation products business between the two parties

$SH PHARMA (02607.HK)$: Drug B019 for recurrent or refractory B-lymphocytic tumors obtained a clinical trial approval notice

$CUTIA-B (02487.HK)$: The phase I clinical trial of CU-40101 (topical small molecule thyroid hormone receptor agonist liniment) in China has reached a major end point

Repurchase cancellation

$JIUMAOJIU (09922.HK)$: It is proposed to repurchase the company's shares on the open market from time to time for a maximum total amount of HK$150 million

$HSBC HOLDINGS (00005.HK)$Repurchase of 2.5 million shares at a cost of HK$142 million on November 1

$AIA (01299.HK)$On November 2, 1,964,400 shares were repurchased at a cost of HK$135 million

$SINOPEC CORP (00386.HK)$On November 2, 9.194,000 shares were repurchased at a cost of HK$373.35 million

$DONGFENG GROUP (00489.HK)$On November 2, it spent HK$35.8774 million to repurchase 10.246,000 shares

$BEKE-W (02423.HK)$On November 1, 1.5 million shares were repurchased at a cost of 7.39 million US dollars

$COSCO SHIP HOLD (01919.HK)$On November 2, 1,803,500 shares were repurchased at HK$14.306,900

$HAIER SMARTHOME (06690.HK)$On November 2, it spent 11.206,000 yuan to repurchase 500,000 A-shares

$HAOHAI BIOTEC (06826.HK)$On November 2, 136,400 shares were repurchased at a cost of HK$5.7923 million

$CONCORD NE (00182.HK)$Repurchase of 5 million shares at a cost of HK$3.2 million on November 2

$BAIRONG-W (06608.HK)$Repurchase of 300,000 shares at a cost of HK$2.92 million on November 2

Editor/Somer